Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes

Blood Adv. 2022 Jun 14;6(11):3551-3555. doi: 10.1182/bloodadvances.2021006277.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP-Binding Cassette Transporters
  • Anemia*
  • Calcium-Calmodulin-Dependent Protein Kinases / genetics
  • Calcium-Calmodulin-Dependent Protein Kinases / metabolism
  • Deferasirox / therapeutic use
  • Humans
  • Iron Chelating Agents

Substances

  • ABCB6 protein, human
  • ATP-Binding Cassette Transporters
  • Iron Chelating Agents
  • Calcium-Calmodulin-Dependent Protein Kinases
  • TRIB2 protein, human
  • Deferasirox